Abstract: Disclosed and claimed are: a composition including at least one glycosaminoglycan, e.g., CIS, at least one perfluorinated substance and at least one alginate, e.g., sodium alginate, wherein:
the at least one glycosaminoglycan and/or the perfluorinated substance and/or the alginate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt; or
the at least one glycosaminoglycan, the perfluorinated substance and the alginate are covalently bound, e.g., by means of a coupling reaction involving a linker molecule such as DVS; or
the at least one glycosaminoglycan and/or the perfluorinated substance and/or the alginate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt, and the at least one glycosaminoglycan and the alginate are covalently bound, e.g.
Type:
Grant
Filed:
January 4, 2000
Date of Patent:
October 7, 2003
Assignees:
Biomm, Inc., Diabetes Research Institute, University of Miami
Inventors:
Christopher Fraker, Luca Inverardi, Marcos Mares-Guia, Camillo Ricordi
Abstract: Disclosed and claimed are: a composition including at least one glycosaminoglycan, e.g., CIS, and at least one alginate, e.g., sodium alginate, wherein:
the at least one glycosaminoglycan and/or the algninate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt; or
the at least one glycosaminoglycan and the alginate are covalently bound, e.g., by means of a coupling reaction involving a linker molecule such as DVS; or
the at least one glycosaminoglycan and/or the algninate are cross-linked or polymerized, e.g., the alginate is cross-linked or polymerized, for instance by addition of an inorganic salt, such as a calcium salt, and the at least one glycosaminoglycan and the alginate are covalently bound, e.g.
Abstract: Non-immunogenic biocompatible macromolecular sheet composition are formed from a cellulosic membrane, a binding moiety having a plurality of functional groups, and a glycosaminoglycan (GAG). The binding moiety has the formula of R1—X—R2 wherein R1 and R2 are the same or different. The binding moiety, through functional groups binds the cellulosic membrane with the glycosaminoglycan. R1 is covalently bound to a carbon or an oxygen of the cellulosic membrane. R2 is covalently bound to a carbon, an oxygen, or a nitrogen of the glycosaminoglycan. The binding moiety can be bis-oxyrane, butanediol-diglycidyl ether (BDE), or divinyl sulfone. The cellulosic membrane can be a cellulosic membrane, partially acetylated cellulose and a copolymer of hydroxyethyl-methacrylate with methyl methacrylate, abbreviated as HEMA-MMA. The non-immunogenic biocompatible macromolecular sheet composition can be formed into a pouch to encapsulate cells, tissues, pharmaceuticals, or biological metabolic products.
Abstract: Non-immunogenic biocompatible macromolecular sheet composition are formed from a cellulosic membrane, a binding moiety having a plurality of functional groups, and a glycosaminoglycan (GAG). The binding moiety has the formula of R.sup.1 --X--R.sup.2 wherein R.sup.1 and R.sup.2 are the same or different. The binding moiety, through functional groups binds the cellulosic membrane with the glycosaminoglycan. R.sup.1 is covalently bound to a carbon or an oxygen of the cellulosic membrane. R.sup.2 is covalently bound to a carbon, an oxygen, or a nitrogen of the glycosaminoglycan. The binding moiety can be bis-oxyrane, butanediol-diglycidyl ether (BDE), or divinyl sulfone. The cellulosic membrane can be a cellulosic membrane, partially acetylated cellulose and a copolymer of hydroxyethyl-methacrylate with methyl methacrylate, abbreviated as HEMA-MMA.